U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.3 Articles
3 Articles
For decades, U.S. biotech startups have disclosed their early research findings to attract investment. But now, to prevent competitors, especially Chinese biopharmaceutical companies, from quickly copying and imitating their products and starting human trials ahead of schedule, more and more U.S. pharmaceutical companies are choosing to keep a low profile and keep their early research findings highly confidential.
U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China
Steve Potts is developing medicines for hard-to-treat cancers. Just don’t ask what, exactly, he is working on. If word gets out, he fears a Chinese company could beat him to market. Potts’s company, whose team has shepherded a combined 13 drugs through Food and Drug Administration approval, is one of a growing number of biotechs […] The post U.S. Biotechs Are Keeping More Secrets to Beat Copycats in China appeared first on OODAloop.
'We're paranoid.' As China biotech competition heats up, American drugmakers get more secretive
Janine Sengstack believes she may have found the next big breakthrough in diabetes and obesity. Her company, Junevity, has searched through hundreds of genes to discover ones that, when repressed, can turn ...
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
